Literature DB >> 2736093

Secure endoscopic sinus surgery as an adjunct to functional nasal surgery.

P H Toffel1, D J Aroesty, R H Weinmann.   

Abstract

The efficacy of functional endoscopic sinus surgery for the treatment of chronic sinusitis is well established. Two contrasting European techniques are currently in use: that espoused by Wigand, which includes endoscopic exenteration of all the sinus cavities with removal of the middle turbinates, and that developed by Messerklinger, who practices minimal opening of the narrow osteomeatal tract at the anterior ethmoidal sinus to achieve physiological reversal of sinus disease. After exposure to both techniques, one of us (P.H.T.) developed a middle-ground approach that lies between the extremes of the two European schools. The benefits of this middle-ground technique include a high success rate, maximal safety, relative ease of learning, and its ability to be performed as an adjunct to any other indicated functional nasal surgery.

Entities:  

Mesh:

Year:  1989        PMID: 2736093     DOI: 10.1001/archotol.1989.01860310060023

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  3 in total

Review 1.  Traditional endonasal and microscopic sinus surgery complications versus endoscopic sinus surgery complications: a meta-analysis.

Authors:  Massimo Re; Humbert Massegur; Giuseppe Magliulo; Luigi Ferrante; Vittorio Sciarretta; Giovanni Farneti; Giovanni Macrì; Vito Mallardi; Ernesto Pasquini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-09       Impact factor: 2.503

2.  Comparative evaluation of middle meatus antrostomy with or without partial middle turbinectomy.

Authors:  S P Gulati; Raman Wadhera; Arvind Kumar; Anshu Gupta; Ajay Garg; Anju Ghai
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-01-06

Review 3.  Risks and medico-legal aspects of endoscopic sinus surgery: a review.

Authors:  M Re; G Magliulo; R Romeo; F M Gioacchini; E Pasquini
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-14       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.